Please note that this summary only contains information from the full scientific abstract: View ESMO Scientific Abstract
This study drug is not approved to treat the conditions under study that are discussed in this summary. Lorlatinib is approved for ALK-positive NSCLC but not ROS1-positive NSCLC.
Researchers must look at the results of many types of studies to understand whether a study drug works, how it works, and whether it is safe to prescribe to patients.
This summary reports the results of only one study. The results of this study might be different from the results of other studies that the researchers look at.
This summary reports the interim results from the study – results may not be the same when the study is complete.
More information can be found in the scientific
abstract of this study, which you can access here:
View ESMO Scientific Abstract
235 East 42nd Street NY,
Phone (United States): +1 212-733-2323
Pfizer would like to thank all of the people who took part in this study.